Search

Your search keyword '"Sumransub, Nuttavut"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Sumransub, Nuttavut" Remove constraint Author: "Sumransub, Nuttavut"
40 results on '"Sumransub, Nuttavut"'

Search Results

1. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

2. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

6. Patients with TP53 -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.

8. Identification of HLA‐Restricted Cytotoxic T Lymphocyte Epitopes of B Cell Maturation Antigen as Promising Peptide Vaccine Candidates for Preventive and Therapeutic Strategies in Multiple Myeloma

10. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era.

11. Identification of HLA‐restricted Cytotoxic T Lymphocyte Epitopes of B Cell Maturation Antigen as Promising Peptide Vaccine Candidates for Preventive and Therapeutic Strategies in Multiple Myeloma.

13. Checkpoint Inhibitors Based Salvage Regimens Lead to Higher Survival in Relapsed Refractory Classic Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

14. Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma

17. Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

18. Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

19. Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.

21. Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

23. Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

25. Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

26. Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

28. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

29. Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer

32. Kikuchi-Fujimoto disease mimicking T-cell lymphoma after COVID-19 vaccination.

34. 39 - Checkpoint Inhibitors Based Salvage Regimens Lead to Higher Survival in Relapsed Refractory Classic Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

40. A case of AL amyloidosis presenting with refractory ventricular fibrillation.

Catalog

Books, media, physical & digital resources